Article

<i>CYP2D6</i> Genotyping for Personalized Therapy of Tamoxifen in Indonesian Women with ER+ Breast Cancer

2021-06-30

Abstract excerpt

Tamoxifen is a Selective Estrogen-Receptor Modulator (SERM) commonly prescribed for standard of care in estrogen receptor positive (ER+) breast cancer as an adjuvant therapy. Tamoxifen is metabolized by CYP2D6 into its active metabolite, endoxifen, which has been known to play an important role in reducing risk of ER+ breast cancer recurrence. CYP2D6 is a highly polymorphic gene with more than 100 alleles. The phe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 728742bc-65c5-5cb3-b0fa-a07d7a8d95a9
DOI: 10.1101/2021.06.25.21259564

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>CYP2D6</i> Genotyping for Personalized Therapy of Tamoxifen in Indonesian Women with ER+ Breast CancerDOI 10.1101/2021.06.25.21259564Read

CYP2D6 Genotyping for Personalized Therapy of Tamoxifen in Indonesian Women with ER+ Breast CancerSemantic proximity Read

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a ControversySemantic proximity Read

CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer PatientsSemantic proximity Read

Use of <i>CYP2D6</i> Genotyping in Practice: Tamoxifen Dose AdjustmentSemantic proximity Read

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.Semantic proximity Read

Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.Semantic proximity Read

Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.Semantic proximity Read

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Semantic proximity Read

Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen.Semantic proximity Read

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.Semantic proximity Read

Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifenSemantic proximity Read

Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.Semantic proximity Read